TET2
genetic predisposition
myeloproliferative neoplasms
single nucleotide polymorphisms
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
23
10
2020
revised:
25
11
2020
accepted:
29
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
12
2020
Statut:
epublish
Résumé
The complexity of myeloproliferative neoplasms (MPNs) cannot be characterized by acquired somatic mutations alone. Individual genetic background is thought to contribute to the development of MPNs. The aim of our study was to assess the association between the We evaluated the Significant association between The
Sections du résumé
BACKGROUND
BACKGROUND
The complexity of myeloproliferative neoplasms (MPNs) cannot be characterized by acquired somatic mutations alone. Individual genetic background is thought to contribute to the development of MPNs. The aim of our study was to assess the association between the
METHODS
METHODS
We evaluated the
RESULTS
RESULTS
Significant association between
CONCLUSIONS
CONCLUSIONS
The
Identifiants
pubmed: 33271790
pii: jpm10040259
doi: 10.3390/jpm10040259
pmc: PMC7711989
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Research and Education, Romania
ID : PN-III-P1-1.1-PD-2016-1414
Références
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921
Blood Adv. 2016 Nov 30;1(2):105-111
pubmed: 29296803
Blood Adv. 2016 Nov 22;1(1):21-30
pubmed: 29296692
Dev Cell. 2013 Feb 11;24(3):310-23
pubmed: 23352810
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71
pubmed: 21873190
N Engl J Med. 2009 May 28;360(22):2289-301
pubmed: 19474426
Br J Haematol. 2016 Jul;174(2):218-26
pubmed: 27061303
Blood. 2016 Aug 25;128(8):1121-8
pubmed: 27365426
Mediterr J Hematol Infect Dis. 2020 Jan 01;12(1):e2020004
pubmed: 31934314
Blood. 2008 Sep 15;112(6):2199-204
pubmed: 18451307
Oncotarget. 2016 Feb 23;7(8):9550-60
pubmed: 26843622
Leukemia. 2014 Jun;28(6):1371-4
pubmed: 24476768
Haematologica. 2011 Nov;96(11):1575-9
pubmed: 22058280
Nature. 2010 Aug 26;466(7310):1129-33
pubmed: 20639862
Nat Commun. 2015 Apr 07;6:6691
pubmed: 25849990
Blood. 2017 Dec 7;130(23):2475-2483
pubmed: 29212804
Case Rep Hematol. 2014;2014:841787
pubmed: 25525531
Nature. 2010 Dec 9;468(7325):839-43
pubmed: 21057493
Nat Genet. 2009 Apr;41(4):450-4
pubmed: 19287385
Nature. 2012 Aug 30;488(7413):652-5
pubmed: 22902501
Front Cell Dev Biol. 2019 Jun 07;7:99
pubmed: 31231651
Leukemia. 1999 Dec;13(12):1901-28
pubmed: 10602411
Leukemia. 2013 Oct;27(10):2032-9
pubmed: 23860450
Cancer. 2009 Sep 1;115(17):3842-7
pubmed: 19472396
Blood. 2005 Sep 15;106(6):2162-8
pubmed: 15920007
Nat Genet. 2009 Apr;41(4):455-9
pubmed: 19287384
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Oct;27(5):1574-1579
pubmed: 31607314
Nat Genet. 2009 Jul;41(7):838-42
pubmed: 19483684
Nat Genet. 2009 Apr;41(4):446-9
pubmed: 19287382
JAMA Oncol. 2015 Apr;1(1):97-105
pubmed: 26182311
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Int J Mol Sci. 2018 Apr 11;19(4):
pubmed: 29641446
Blood. 1951 Apr;6(4):372-5
pubmed: 14820991
Am J Hematol. 2018 Jan;93(1):100-106
pubmed: 29047144